Microprojection array immunization patch and method

• US 20050025778A1
• Filed: 07/01/2004
• Published: 02/03/2005
• Est. Priority Date: 07/02/2003
• Status: Abandoned Application

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Daddona, Peter E., Young, Wendy A., Johnson, Juanita A., Cormier, Michel J.N., Matriano, James
• Application Number:
  US10/884,603
• Publication Number:
  US 20050025778A1
• Time in Patent Office: Days
• US Class Current: 424/185.100
• CPC Class Codes: A61B 17/205 Vaccinating by means of needles or other puncturing devices
• CPC Class Codes: A61K 9/0021 Intradermal administration, e.g. through microneedle arrays, needleless injectors mechanical aspects A61M
• CPC Class Codes: A61M 2037/0023 Drug applicators using microneedles
• CPC Class Codes: A61M 2037/0046 Solid microneedles
• CPC Class Codes: A61M 37/0015 by using microneedles
• CPC Class Codes: A61P 37/04 Immunostimulants

Abstract

Microprojection members (10) having a reservoir containing an antigenic agent and methods of using such members to vaccinate mammals (e.g., humans) are disclosed. The microprojection members are used to transdermally deliver an antigenic agent (e.g., a vaccine antigen) with substantially reduced skin reactions. This is achieved by delivering an induction amount and thereafter delivering one or more subsequent booster amounts. The induction amount is relatively larger than the booster amount. This technology has broad applicability for a wide variety of therapeutic vaccines to improve efficacy and convenience of use.

Claims

1. A method for delivering an antigenic agent to a mammal, comprising:

providing at least two transdermal delivery members, each of said members including a plurality of microprojections configured to pierce the stratum corneum and a reservoir containing a loading amount of said antigenic agent, said reservoir being adapted to be positioned in antigenic agent-transmitting relation with the mammal when the delivery member is applied to a skin site of the mammal;

delivering with a first of said at least two transdermal delivery members an induction amount of said antigenic agent;

delivering with a second of said at least two transdermal delivery members a first booster amount of said antigenic agent at least about 7 days after said delivery of said induction amount of said antigenic agent, said booster amount comprising up to about 50% by weight of said induction amount.

2. The method of claim 1, wherein said induction amount of said antigenic agent is at least about 10 micrograms and said first booster amount of said antigenic agent is below about 5 micrograms.

3. The method of claim 1, wherein said first booster amount of said antigenic agent is delivered at least 14 days after said step of delivering said induction amount of said antigenic agent.

4. The method of claim 1, wherein said loading amount of said antigenic agent is substantially the same in said first and second transdermal delivery members, wherein said step of delivering said induction amount of said antigenic agent comprises leaving said first transdermal delivery member in contact with said mammal for a first period of time and said step of delivering said first booster amount of said antigenic agent comprises than leaving said second transdermal delivery member in contact with said mammal for a second period of time and wherein said first period of time is longer than said second period of time.

5. The method of claim 4, wherein said first period of time is at least about 0.5 hours.

6. The method of claim 5, wherein said second period of time is less than about 0.25 hours.

7. The method of claim 1, wherein said first transdermal delivery member has a loading amount of said antigenic agent greater than the loading amount of said antigenic agent of said second transdermal delivery member.

8. The method of claim 7, wherein said first delivery member is left in skin piercing contact with the mammal for about the same period of time as said second delivery member.

9. The method of claim 1, including delivering a second booster amount of said antigenic agent with a third transdermal delivery member at least about 7 days following said step of delivering said first booster amount of said antigenic agent.

10. The method of claim 1, wherein said first and second transdermal delivery members are comprised of metal and include an adhesive backing.

11. The method of claim 1, wherein said first and second transdermal delivery members pierce the skin over a skin contact area of less than 5 cm².

12. The method of claim 1, further comprising the step of substantially reducing local skin reactions to said antigenic agent.

13. The method of claim 1, wherein said antigenic agent is selected from the group consisting of proteins, polysaccharide conjugates, oligosaccharides, lipoproteins, subunit vaccines, Bordetella pertussis (recombinant PT accince—

acellular), Clostridium tetani (purified, recombinant), Corynebacterium diptheriae (purified, recombinant), Cytomegalovirus (glycoprotein subunit), Group A streptococcus (glycoprotein subunit, glycoconjugate Group A polysaccharide with tetanus toxoid, M protein/peptides linked to toxing subunit carriers, M protein, multivalent type-specific epitopes, cysteine protease, C5a peptidase), Hepatitis B virus (recombinant Pre S1, Pre-S2, S, recombinant core protein), Hepatitis C virus (recombinant—

expressed surface proteins and epitopes), Human papillomavirus (Capsid protein, TA-GN recombinant protein L2 and E7 [from HPV-6], MEDI-501 recombinant VLP L1 from HPV-11, Quadrivalent recombinant BLP L1 [from HPV-6], HPV-11, HPV-16, and HPV-18, LAMP-E7 [from HPV-16]), Legionella pneumophila (purified bacterial survace protein), Neisseria meningitides (glycoconjugate with tetanus toxoid), Pseudomonas aeruginosa (synthetic peptides), Rubella virus (synthetic peptide), Streptococcus pneumoniae (glyconconjugate [1, 4, 5, 6B, 9N, 14, 18C, 19V, 23F] conjugated to meningococcal B OMP, glycoconjugate [4, 6B, 9V, 14, 18C, 19F, 23F] conjugated to CRM197, glycoconjugate [1, 4, 5, 6B, 9V, 14, 18C, 19F, 23F] conjugated to CRM1970, Treponema pallidum (surface lipoproteins), Varicella zoster virus (subunit, glycoproteins), Vibrio cholerae (conjugate lipopolysaccharide), whole virus, bacteria, weakened or killed viruses, cytomegalo virus, hepatitis B virus, hepatitis C virus, human papillomavirus, rubella virus, varicella zoster, weakened or killed bacteria, bordetella pertussis, clostridium tetani, corynebacterium diptheriae, group A streptococcus, legionella pneumophila, neisseria meningitdis, pseudomonas aeruginosa, streptococcus pneumoniae, treponema pallidum, vibrio cholerae, flu vaccines, lyme disease vaccine, rabies vaccine, measles vaccine, mumps vaccine, chicken pox vaccine, small pox vaccine, hepatitis vaccine, pertussis vaccine, diptheria vaccine, nucleic acids, single-stranded and double-stranded nucleic acids, supercoiled plasmid DNA, linear plasmid DNA, cosmids, bacterial artificial chromosomes (BACs), yeast artificial chromosomes (YACs), mammalian artificial chromosomes, and RNA molecules.

14. The method of claim 1, wherein the reservoir includes an immunologically potentiating adjuvant.

15. The method of claim 14, wherein said adjuvant is selected from the group consisting of aluminum phosphate gel, aluminum hydroxide, algal glucan, β

-glucan, cholera toxin B subunit, CRL1005, ABA block polymer with mean values of x=8 and y=205, gamma insulin, linear (unbranched) β

-D(2->

1) polyfructofuranoxyl-α

-D-glucose, Gerbu adjuvant, N-acetylglucosamine-(β

1-4)-N-acetylmuramyl-L-alanyl-D-glutamine (GMDP), dimethyl dioctadecylammonium chloride (DDA), zinc L-proline salt complex (Zn-Pro-8), Imiquimod (1-(2-methypropyl)-1H-imidazo[4,5-c]quinolin-4-amine, ImmTher™

, N-acetylglucoaminyl-N-acetylmuramyl-L-Ala-D-isoGlu-L-Ala-glycerol dipalmitate, MTP-PE liposomes, C₅₉H₁₀₈N₆O₁₉PNa-3H₂O (MTP), Murametide, Nac-Mur-L-Ala-D-Gln-OCH₃, Pleuran, β

-glucan, QS-21;

S-28463, 4-amino-a, a-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, sclavo peptide, VQGEESNDK.HCl (IL-1β

163-171 peptide), threonyl-MDP (Termurtide™

), N-acetyl muramyl-L-threonyl-D-isoglutamine, interleukin 18, IL-2 IL-12, IL-15, DNA oligonucleotides, CpG containing oligonucleotides, gamma interferon, NF kappa B regulatory signaling proteins, heat-shock proteins (HSPs), GTP-GDP, Loxoribine, MPL®

, Murapalmitine, and Theramide™

.

16. The method of claim 1, wherein said reservoir includes a hydrogel formulation.

17. The method of claim 16, wherein said hydrogel formulation comprises a macromolecular polymeric network.

18. The method of claim 17, wherein said macromolecular polymeric network is selected from the group consisting of hydroxyethylcellulose (HEC), hydroxypropylmethylcellulose (HPMC), hydroxypropycellulose (HPC), methylcellulose (MC), hydroxyethylmethylcellulose (HEMC), ethylhydroxyethylcellulose (EHEC), carboxymethyl cellulose (CMC), poly(vinyl alcohol), poly(ethylene oxide), poly(2-hydroxyethylmethacrylate), poly(n-vinyl pyrolidone), and pluronics.

19. The method of claim 1, wherein said reservoir comprises a coating disposed on at least one of said first and second delivery members.

20. The method of claim 19, wherein said coating further includes a low volatility counterion.

21. The method of claim 20, wherein said low volatility counterion is selected from the group consisting of maleic acid, malic acid, malonic acid, tartaric acid, adipic acid, citraconic acid, fumaric acid, glutaric acid, itaconic acid, meglutol, mesaconic acid, succinic acid, citramalic acid, tartronic acid, citric acid, tricarballylic acid, ethylenediaminetetraacetic acid, aspartic acid, glutamic acid, carbonic acid, sulfuric acid, and phosphoric acid, and mixtures thereof.

22. The method of claim 20, wherein said low volatility counterion is selected from the group consisting of monoethanolomine, diethanolamine, triethanolamine, tromethamine, methylglucamine, glucosamine, histidine, lysine, arginine, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, ammonia and morpholine, and mixtures thereof.

23. The method of claim 1, wherein said reservoir includes a surfactant.

24. The method of claim 23, wherein said surfactant is selected from the group consisting of sodium lauroamphoacetate, sodium dodecyl sulfate (SDS), cetylpyridinium chloride (CPC), dodecyltrimethyl ammonium chloride (TMAC), benzalkonium, chloride, polysorbates, such as Tween 20 and Tween 80, sorbitan derivatives, sorbitan laurate, alkoxylated alcohols, and laureth-4.

25. The method of claim 1, wherein said reservoir includes an amphiphilic polymer.

26. The method of claim 25, wherein said amphiphilic polymer is selected from the group consisting of cellulose derivatives, hydroxyethylcellulose (HEC), hydroxypropyl-methylcellulose (HPMC), hydroxypropycellulose (HPC), methylcellulose (MC), hydroxyethylmethylcellulose (HEMC), ethylhydroxyethylcellulose (EHEC), and pluronics.

27. The method of claim 1, wherein said reservoir includes a pathway patency modulator.

28. The method of claim 27, wherein said pathway patency modulator is selected from the group consisting of osmotic agents, sodium chloride, zwitterionic compounds, amino acids, anti-inflammatory agents, betamethasone 21-phosphate disodium salt, triamcinolone acetonide 21-disodium phosphate, hydrocortamate hydrochloride, hydrocortisone 21-phosphate disodium salt, methylprednisolone 21-phosphate disodium salt, methylprednisolone 21-succinaate sodium salt, paramethasone disodium phosphate, prednisolone 21-succinate sodium salt, anticoagulants, citric acid, citrate salts, sodium citrate, dextran sulfate sodium, and EDTA.

29. The method of claim 1, wherein said reservoir includes a vasoconstrictor.

30. The method of claim 29, wherein said vasoconstrictor is selected from the group consisting of epinephrine, naphazoline, tetrahydrozoline indanazoline, metizoline, tramazoline, tymazoline, oxymetazoline, xylometazoline, amidephrine, cafaminol, cyclopentamine, deoxyepinephrine, epinephrine, felypressin, indanazoline, metizoline, midodrine, naphazoline, nordefrin, octodrine, omipressin, oxymethazoline, phenylephrine, phenylethanolamine, phenylpropanolamine, propylhexedrine, pseudoephedrine, tetrahydrozoline, tramazoline, tuaminoheptane, tymazoline, vasopressin and xylometazoline.

31. The method of claim 1, wherein said reservoir includes an antioxidant.

32. The method of claim 31, wherein said antioxidant is selected from the group consisting of sodium citrate, citric acid, ethylene-dinitrilo-tetraacetic acid (EDTA), ascorbic acid, methionine, and sodium ascorbate.

33. The method of claim 1, wherein said reservoir includes a solubilising/complexing agent.

34. The method of claim 33, wherein said solubilising/complexing agent is selected from the group consisting of Alpha-Cyclodextrin, Beta-Cyclodextrin, Gamma-Cyclodextrin, glucose-alpha-Cyclodextrin, maltosyl-alpha-Cyclodextrin, glucosyl-beta-Cyclodextrin, maltosyl-beta-Cyclodextrin, hydroxypropyl beta-cyclodextrin, 2-hydroxypropyl-beta-Cyclodextrin, 2-hydroxypropyl-gamma-Cyclodextrin, hydroxyethyl-beta-Cyclodextrin, methyl-beta-Cycl odextrin, sulfobutylether-alpha-cyclodextrin, sulfobutylether-beta-cyclodextrin, and sulfobutylether-gamma-cyclodextrin.

35. The method of claim 1, wherein said mammal comprises a human.

36. A method for vaccinating a mammal, comprising:

providing at least two transdermal delivery members, each of said members comprising at least one microprojection configured to pierce the stratum corneum and a reservoir having a loading amount of an antigenic agent, said reservoir being positioned in antigenic agent-transmitting relation with said mammal;

delivering with a first of said at least two transdermal delivery members an induction amount of said antigenic agent;

delivering with a second of said at least two transdermal delivery members a booster amount of said antigenic agent at least about 7 days thereafter, said booster amount being up to about 50% by weight of said induction amount.

37. A method for vaccinating a mammal, comprising:

providing at least two transdermal delivery members, each of said members comprising at least one microprojection configured to pierce the stratum corneum and a reservoir having a loading amount of an antigenic agent, said reservoir being positioned in antigenic agent-transmitting relation with said mammal;

delivering with a first of said at least two transdermal delivery members an induction amount of said antigenic agent;

delivering with a second of said at least two transdermal delivery members a booster amount of said antigenic agent, said booster amount being up to about 50% by weight of said induction amount.